Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.

Published

Journal Article

AIM: The authors assessed the comparative effectiveness of torsemide versus furosemide in the PROTECT trial. METHODS: The authors assessed the relationship between loop diuretic at discharge and death or cardiovascular/renal hospitalization within 30 days, and death through 150 days postdischarge using inverse probability weighting. RESULTS: Out of 1004 patients, 83.5% received furosemide and 16.5% torsemide. Torsemide patients had higher blood urea nitrogen, and more in-hospital worsening heart failure. Following adjustment, torsemide was associated with similar 30-day outcomes compared with furosemide (p = 0.93), but remained associated with increased 150-day death (hazard ratio: 2.26; 95% CI: 1.40-3.66; p < 0.001). CONCLUSION: Patients treated with torsemide had features of greater disease severity, similar 30-day outcomes but increased 150-day mortality. Prospective randomized trials are needed to investigate the effect of torsemide versus furosemide.

Full Text

Duke Authors

Cited Authors

  • Mentz, RJ; Velazquez, EJ; Metra, M; McKendry, C; Chiswell, K; Fiuzat, M; Givertz, MM; Voors, AA; Teerlink, JR; O'Connor, CM

Published Date

  • September 2015

Published In

Volume / Issue

  • 11 / 5

Start / End Page

  • 585 - 595

PubMed ID

  • 26403536

Pubmed Central ID

  • 26403536

Electronic International Standard Serial Number (EISSN)

  • 1744-8298

Digital Object Identifier (DOI)

  • 10.2217/fca.15.56

Language

  • eng

Conference Location

  • England